ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer
Results of a retrospective study presented during the 2021 American [...]
ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer
The past couple of years has seen a number of [...]
Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer
The microbes in the gut (the gut microbiome) are a [...]
Cabozantinib plus nivolumab granted FDA approval for first-line treatment of advanced kidney cancer
The Food and Drug Administration (FDA) in the United States has [...]
Obesity diminishes response to immunotherapy in kidney cancer
In this study, the researchers looked at the interaction between [...]
Obesity and kidney cancer
A large review of the data showed that cancer specific [...]
Percutaneous thermoablation for small renal masses
This study looked at the survival of patients suitable for [...]
CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival
The US Food and Drug Administration (FDA) has granted the [...]
Nivolumab plus ipilimumab for first-line treatment of advanced kidney cancer: Extended 4-year follow-up
Four-year follow up data are now available from the CheckMate [...]
Future for VHL kidney cancer is bright
Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always [...]
